OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
THG60

Thonburi Healthcare Group PCL

Healthcare Facilities & ServicesVerified

Thonburi Healthcare Group PCL maintains a relatively conservative capital structure, with a debt-to-equity ratio of 0.28, indicating a low reliance on debt financing. The company's liquidity position is characterized as medium, with a current ratio of 1.33, suggesting it can cover its short-term obligations but with limited buffer. However, the company's net cash position is negative after subtracting total debt, which could pose a liquidity risk if cash flow from operations is disrupted. In terms of profitability, the company's return on equity (ROE) is 0.72%, and its return on assets (ROA) is 0.47%, both of which are below the industry median for healthcare facilities and services. This suggests that the company is underperforming relative to its peers in terms of capital efficiency and asset utilization. The operating margin, calculated as operating income divided by revenue, is 5.45%, which is also below the industry median, indicating that the company is generating less profit per unit of revenue compared to its competitors. Geographically, the company's revenue is concentrated in Thailand, with no significant international exposure disclosed in the available data. The company operates in a single business segment, which is typical for a healthcare services provider in the region. However, the lack of diversification could expose the company to local economic and regulatory risks. The company's growth trajectory is modest, with no significant revenue growth reported in the latest financial period. The operating cash flow of 1.18 billion THB and free cash flow of 399.5 million THB indicate that the company is generating positive cash from operations, but the capital expenditure of -896.55 million THB suggests that the company is investing in its operations to maintain or expand its service offerings. Analysts have assigned a neutral recommendation to the stock, with a mean price target of 7.20 THB, which is unchanged from the median and high/low targets, indicating a lack of consensus on the stock's future performance. The company's risk profile is characterized by a low dilution risk, with no significant dilution potential identified in the latest financial data. However, the negative net cash position after debt is a red flag, as it could lead to increased borrowing or equity issuance in the future, which could dilute existing shareholders. The company's liquidity risk is moderate, as it has sufficient current assets to cover its short-term liabilities, but the lack of a strong cash buffer could be a concern in a downturn. Recent events, including the latest financial filing, show that the company is maintaining a stable financial position, with no major one-time charges or restructuring activities reported. The company's credit risk is low, as it has a strong equity base and manageable debt levels. However, the company's exposure to regulatory changes in the healthcare sector could impact its operations and profitability in the future.

30-day price · THG-1.25 (-14.0%)
Low$7.40High$9.05Close$7.65As of22 May, 00:00 UTC
Profile
CompanyThonburi Healthcare Group PCL
TickerTHG.BK
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryHealthcare Facilities & Services
AI analysis

Business. Thonburi Healthcare Group PCL operates in the healthcare facilities and services industry, providing pharmaceutical and healthcare services to patients in Thailand and potentially other markets.

Classification. Thonburi Healthcare Group PCL is classified under the Healthcare sector, specifically in the Healthcare Facilities & Services industry, with a high confidence level of 0.92 based on verified market data.

Thonburi Healthcare Group PCL maintains a relatively conservative capital structure, with a debt-to-equity ratio of 0.28, indicating a low reliance on debt financing. The company's liquidity position is characterized as medium, with a current ratio of 1.33, suggesting it can cover its short-term obligations but with limited buffer. However, the company's net cash position is negative after subtracting total debt, which could pose a liquidity risk if cash flow from operations is disrupted. In terms of profitability, the company's return on equity (ROE) is 0.72%, and its return on assets (ROA) is 0.47%, both of which are below the industry median for healthcare facilities and services. This suggests that the company is underperforming relative to its peers in terms of capital efficiency and asset utilization. The operating margin, calculated as operating income divided by revenue, is 5.45%, which is also below the industry median, indicating that the company is generating less profit per unit of revenue compared to its competitors. Geographically, the company's revenue is concentrated in Thailand, with no significant international exposure disclosed in the available data. The company operates in a single business segment, which is typical for a healthcare services provider in the region. However, the lack of diversification could expose the company to local economic and regulatory risks. The company's growth trajectory is modest, with no significant revenue growth reported in the latest financial period. The operating cash flow of 1.18 billion THB and free cash flow of 399.5 million THB indicate that the company is generating positive cash from operations, but the capital expenditure of -896.55 million THB suggests that the company is investing in its operations to maintain or expand its service offerings. Analysts have assigned a neutral recommendation to the stock, with a mean price target of 7.20 THB, which is unchanged from the median and high/low targets, indicating a lack of consensus on the stock's future performance. The company's risk profile is characterized by a low dilution risk, with no significant dilution potential identified in the latest financial data. However, the negative net cash position after debt is a red flag, as it could lead to increased borrowing or equity issuance in the future, which could dilute existing shareholders. The company's liquidity risk is moderate, as it has sufficient current assets to cover its short-term liabilities, but the lack of a strong cash buffer could be a concern in a downturn. Recent events, including the latest financial filing, show that the company is maintaining a stable financial position, with no major one-time charges or restructuring activities reported. The company's credit risk is low, as it has a strong equity base and manageable debt levels. However, the company's exposure to regulatory changes in the healthcare sector could impact its operations and profitability in the future.
Key takeaways
  • Thonburi Healthcare Group PCL has a conservative capital structure with a debt-to-equity ratio of 0.28.
  • The company's ROE and ROA are below the industry median, indicating underperformance in capital efficiency.
  • The company's revenue is concentrated in Thailand, with no significant international exposure.
  • Analysts have assigned a neutral recommendation to the stock, with a mean price target of 7.20 THB.
  • The company's liquidity risk is moderate, with a current ratio of 1.33 but a negative net cash position after debt.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyTHB
Revenue$9.10B
Gross profit$2.06B
Operating income$495.3M
Net income$96.2M
R&D
SG&A
D&A
SBC
Operating cash flow$1.18B
CapEx-$896.6M
Free cash flow$399.5M
Total assets$20.45B
Total liabilities$7.01B
Total equity$13.44B
Cash & equivalents$3.4M
Long-term debt$3.80B
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$13.44B
Net cash-$3.79B
Current ratio1.3
Debt/Equity0.3
ROA0.5%
ROE0.7%
Cash conversion12.3%
CapEx/Revenue-9.9%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Pharmaceuticals · cohort 779 companies
MetricTHGActivity
Op margin5.4%7.7% medp25 -2.4% · p75 15.5%below median
Net margin1.1%5.9% medp25 -3.8% · p75 12.8%below median
Gross margin22.6%45.5% medp25 31.1% · p75 62.9%bottom quartile
R&D / revenue529.2% medp25 465.2% · p75 593.2%
CapEx / revenue-9.9%-7.0% medp25 -14.9% · p75 -3.2%below median
Debt / equity28.0%25.0% medp25 3.8% · p75 63.3%above median
Observations
IR observations
Mean price target7.20 THB
Median price target7.20 THB
High price target7.20 THB
Low price target7.20 THB
Mean recommendation5.00 (1=strong buy, 5=strong sell)
Strong-buy count0.00
Buy count0.00
Hold count0.00
Sell count0.00
Strong-sell count1.00
Mean EPS estimate0.36 THB
Last actual EPS0.08 THB
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod financials
no public URL
2026-05-24 15:15 UTC#e55f5e3c
Source: analysis-pipeline (hybrid)Generated: 2026-05-29 17:11 UTCJob: 3d6c6668